Sanger Validation of High-Throughput Sequencing in Genetic Diagnosis: Still the Best Practice?

Rosina De Cario; Ada Kura; Samuele Suraci; Alberto Magi; Andrea Volta; Rossella Marcucci; Anna Maria Gori; Guglielmina Pepe; Betti Giusti; Elena Sticchi

doi:10.3389/fgene.2020.592588

Sanger Validation of High-Throughput Sequencing in Genetic Diagnosis: Still the Best Practice?

Front Genet. 2020 Dec 2:11:592588. doi: 10.3389/fgene.2020.592588. eCollection 2020.

Authors

Rosina De Cario¹, Ada Kura¹, Samuele Suraci¹, Alberto Magi², Andrea Volta¹, Rossella Marcucci^{1

3}, Anna Maria Gori^{1

3}, Guglielmina Pepe^{1

3}, Betti Giusti^{1

3}, Elena Sticchi^{1

3}

Affiliations

¹ Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
² Department of Information Engineering, University of Florence, Florence, Italy.
³ Atherothrombotic Diseases Center, Careggi University Hospital, Florence, Italy.

Abstract

Next-generation sequencing (NGS)'s crucial role in supporting genetic diagnosis and personalized medicine leads to the definition of Guidelines for Diagnostic NGS by the European Society of Human Genetics. Factors of different nature producing false-positive/negative NGS data together with the paucity of internationally accepted guidelines providing specified NGS quality metrics to be followed for diagnostics purpose made the Sanger validation of NGS variants still mandatory. We reported the analysis of three cases of discrepancy between NGS and Sanger sequencing in a cohort of 218 patients. NGS was performed by Illumina MiSeq^® and Haloplex/SureSelect protocols targeting 97 or 57 or 10 gene panels usually applied for diagnostics. Variants called following guidelines suggested by the Broad Institute and identified according to MAF <0.01 and allele balance >0.2 were Sanger validated. Three out of 945 validated variants showed a discrepancy between NGS and Sanger. In all three cases, a deep evaluation of the discrepant gene variant results and methodological approach allowed to confirm the NGS datum. Allelic dropout (ADO) occurrence during polymerase chain or sequencing reaction was observed, mainly related to incorrect variant zygosity. Our study extends literature data in which almost 100% "high quality" NGS variants are confirmed by Sanger; moreover, it demonstrates that in case of discrepancy between a high-quality NGS variant and Sanger validation, NGS call should not be a priori assumed to represent the source of the error. Actually, difficulties (i.e., ADO, unpredictable presence of private variants on primer-binding regions) of the so-called gold standard direct sequencing should be considered especially in light of the constantly implemented and accurate high-throughput technologies. Our data along with literature raise a discussion on the opportunity to establish a standardized quality threshold by International Guidelines for clinical NGS in order to limit Sanger confirmation to borderline conditions of variant quality parameters and verification of correct gene variant call/patient coupling on a different blood sample aliquot.

Keywords: Sanger sequencing; allelic drop-out; discrepancy; high-throughput sequencing; next generation sequencing; sequencing validation; variant call quality.